DNA Enabled Therapeutics
Reliant on DNA as a critical starting material, these treatments represent the next generation of advanced therapeutics, and are beginning to show unprecedented therapeutic outcomes in many devastating diseases
Advantages of dbDNA™
dbDNA™ constructs are the optimal starting material for the production of the next generation of DNA enabled therapeutics. Key benefits of dbDNA™ include:
Removal of antibiotic resistance dbDNA™ eliminates antibiotic selection markers present in pDNA and risk of delivering unwanted sequences .
Commercial scale dbDNA™ is linearly scalable through the multi-gram scale and because it is in vitro, is not susceptible to yield loss when amplifying complicated secondary structures (e.g. ITRs, LTRs and PolyA tails).
Rapid process for speed to market cGMP dbDNA™ production is a two-week process, including QC.
Significant cost reduction Scaled cGMP dbDNA™ production costs are an order of magnitude less than pDNA.
Viral gene therapy
Use of modified viruses as gene delivery vehicles to correct diseases caused by faulty gene expression. DNA is the critical starting material for the production of viral vectors for gene therapy.
Administration of live modified cells to a patient with the potential to transform the treatment paradigm for multiple diseases including cancer. DNA is the critical starting material used to modify cells prior to administration.
mRNA transmits information encoded on DNA and has huge potential to transform the vaccine and gene therapy treatment landscapes. mRNA requires a DNA template in order to be manufactured.
Direct modification of the genome using engineered nucleases with a wide range of therapeutic and non-therapeutic applications. DNA is the donor material for gene editing applications.